The initial nearshoring wave delivered anchor OEM commitments. The second wave — tier-two component supplier investment — is now landing at scale in the Bajio corridor.
The filings invert the premise on two of its three legs — every GPU-secured instrument on the record is deliberately SHORT and amortising against its asset (CoreWeave depreciates technology equipment over 6 years, DDTL 4.0 matures March 2032, DDTL 5.0 runs approximately 5.5 years in quarterly instalments, and only $4,338m of $21,615m of principal falls due after 2030), and not one financing vehicle is offshore ("Cayman" appears zero times in CoreWeave's 10-K, Meta's 10-K and Nebius's 424B5) — leaving the one leg that holds decisively as the story: the collateral does no rating work, because the same sponsor, the same GPU collateral and the same arrangers produce A3/A (low) paper at SOFR+2.25% when the customer is investment grade and Ba2/BB+ paper at SOFR+4.50% when it is not, a 225bp gap of pure counterparty credit, while the only genuinely long bond in the chain — Beignet Investor LLC's $27.3bn 6.581% notes due 2049-05-30, against Meta's "initial four-year lease term" and a residual value guarantee with a threshold of approximately $28bn — is a real-estate deal in which the four years is how long Meta has agreed to rent a building, not how long a GPU lasts.
Non-oil GDP has grown faster than the oil sector for five consecutive years and is now structurally larger. The diversification is real, measurable and self-reinforcing.
The pre-funding requirement has been resolved, the foreign-room mechanism is finally working — only foreign ownership limits stand between Vietnam and EM status.
Office-loan workouts are mostly resolved, reserve builds have peaked, and the regional bank multiples are now re-rating off cleaner balance sheets.
After years of public resistance, the Government Pension Fund Global is preparing to add an unlisted-equity sleeve — and the scale matters.
A modest reduction in capex guidance from the largest hyperscaler tells the supply chain that the upward revision cycle has reached its ceiling.
When the country's largest retailer cannot make in-store primary care work, the diagnosis is not corporate execution — it is that the unit economics of clinic-based care defeat scale.